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Introduction
Nicotine is an addictive substance that is typically consumed 
via cigarettes,1 the primary commercial source of nicotine 
worldwide.2,3 The World Health Organization estimated that 
tobacco products cause 6 million deaths annually worldwide; 
frequency of tobacco-related deaths is expected to rise to 8 mil-
lion per year by 2030.4 Nicotine sustains and drives cigarette 
addiction and consumption and its related morbidity and 
mortality.5
Nicotine from a cigarette is absorbed from the lungs into 
the blood stream. As a tertiary amine it binds to nicotinic cho-
linergic receptors in the central nervous system (CNS) and 
peripheral nervous system (PNS). Among other effects, bind-
ing of these receptors leads to the release of a neurotransmitter, 
dopamine, and activates the rewards pathway. Repeated con-
sumption of nicotine can lead to neuroadaptation, dependence, 
mood/arousal modulation, and withdrawal symptoms if con-
sumption is lowered or stopped.5 Over the past decade, studies 
exploring the cognitive performance effects of nicotine have 
found inconsistent outcomes.6 Some studies reported detri-
mental effects of nicotine while others reported nicotine 
induced cognitive enhancement.5–11
Tobacco companies argue that nicotine has positive effects 
on cognition. British American Tobacco Company (BAT), for 
example, recommends the use of nicotine to help with mood 
and concentration.10 A consumer-oriented pamphlet from 
BAT aggregated statements from various groups supporting 
the use of nicotine,10 which claimed the UK Royal College of 
Physicians stated that medicinal nicotine is “no more harmful 
than the existing use of caffeine”12 and that the National 
Institute for Health and Care Excellence (NICE), UK, stated 
that, “Evidence is available from studies with up to 5 years fol-
low-up which suggests that “pure” nicotine, in the form availa-
ble in nicotine replacement therapy (NRT) products, does not 
pose a significant health risk.”13 Advocates promoting e-ciga-
rette use rely on claims that nicotine has cognitive benefits to 
advance the case that these products should be less unregulated 
and widely available.14,15
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In 1994 a review of 101 studies on the effect of nicotine on 
human performance found nicotine could enhance finger tap-
ping and motor sensory responses in the setting of a cognitive 
task associated attention.16 This enhancement was not observed 
in terms of increased cognitive function.16 Biased scientific 
conclusions may arise with industry funding, particularly for 
the tobacco and pharmaceutical industries, both of which pro-
duce and sell products containing nicotine.17,18 A 1997 follow-
up found that funding by tobacco companies was significantly 
related to study outcome19 after coding 91 studies for: 1) the 
reported conclusion on the cognitive performance effects of 
nicotine and 2) “acknowledged sponsorship”19 divided into two 
categories, non-industry and tobacco industry. Studies (n = 35, 
38%) with acknowledged tobacco industry support were sig-
nificantly more likely to report “conclusions favorable to the 
tobacco industry.”19 In 2010 a meta-analysis of 41 studies on 
the reported cognitive performance effects of nicotine in 
healthy volunteers found nicotine had significant effects on 
memory, motor abilities, and attention.6 Although this study 
included funding source, only a small number of studies 
reported industry funding and the authors did not formally 
investigate a relationship between tobacco industry funding 
and reported study outcomes.6 Overall, existing studies assess-
ing the cognitive performance effects of nicotine have found 
inconsistent results that may be influenced by conflicts of inter-
est, making it challenging to ascertain the effects of nicotine on 
cognition.
We expanded on past research by completing a systematic 
review of the primary literature on the cognitive performance 
effects of nicotine relative to human performance using studies 
published after the most recent 2010 meta-analysis.6 We spe-
cifically focused on studies published after 2009 because 
tobacco industry priorities shifted when the FDA was granted 
regulatory authority over tobacco in 2009.20 This regulatory 
change specifically allowed the FDA to regulate the amount of 
nicotine in tobacco products,20 and created new urgency for 
generating evidence that nicotine had benefits as well as risks. 
At the time two-thirds of smokers supported nicotine reduc-
tion in cigarettes,21 however the industry had found in internal 
research that nicotine was critical to smoker satisfaction and 
continuing use.22 Evidence of possible benefits of nicotine use 
could provide counterarguments to regulation in the event that 
the FDA exercised this authority. This particular tobacco 
industry concern was validated in 2017 when the FDA 
announced its intention to reduce nicotine in combustible cig-
arettes to non-addictive levels.23
We reviewed previously-secret internal tobacco industry 
documents, in addition to published funding disclosures, to 
assess whether study authors had received past tobacco indus-
try funding. We hypothesized that studies with tobacco or 
pharmaceutical industry affiliation would be more likely to 
report nicotine having a beneficial cognitive effect relative to 
studies that did not.
This review addressed three primary research questions:
•• What are the reported cognitive performance effects of 
nicotine on the brain specific to human performance (eg, 
memory, attention, and motor sensory)?
•• Were there any reported adverse cognitive performance 
effects of nicotine on the brain? If so, what?
•• Did any of the included studies involve pharmaceutical 
and/or tobacco industry funding or affiliations? If so, 
how was the funding and/or affiliation reported (eg, dis-
closed funding, affiliation stated, no funding/affiliation 
was disclosed, funding/affiliation discovered by cross ref-
erencing author(s) to lists of tobacco company funded 
research)?
Methods
We conducted a systematic review of journal articles published 
between 2009 and 2016. Data collection was completed July 
1-11, 2016 at the University of California San Francisco (San 
Francisco, CA USA).
Inclusion and exclusion criteria
We adapted inclusion and exclusion from a 2010 review on the 
effect of nicotine and tobacco smoking in human performance6 
as follows: 1) randomized double blinded placebo-control trial; 
2) investigated the cognitive performance effects of nicotine 
after acute administration of nicotine; 3) nicotine was adminis-
tered to healthy adults (18-60 years) who were either nonsmok-
ers, non-deprived smokers, or minimally deprived smokers 
(<2 hours of abstaining from smoking); 4) route of nicotine 
was inhaled, transdermal, oral, injected, or intranasal during a 
laboratory session; 5) publication between 2009-2016 in 
English; 6) peer reviewed journal article; and 7) participants 
had no past medical history of mental illness, Parkinson’s dis-
ease, seizures, and/or dementia.
Outcomes
Participants completed cognitive tasks after nicotine adminis-
tration. These tasks were classified into different performance 
domains, which made up the primary study outcomes. Following 
the classification strategy from the 2010 meta-analysis,6 cogni-
tive tasks were classified into one or more of the following per-
formance domains: attention, long term memory, working 
memory, short term memory, reasoning, and motor sensory 
skills. Secondary outcomes included reported adverse events 
and effects such as a change in blood pressure, change in heart 
rate, and/or mood of the participants administered nicotine.
Search strategy
We conducted a literature search using PubMed, EMBASE, 
PsycINFO, BIOSIS, and Web of Science. Key words included: 
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nicotine, tobacco products, smoking, cigarette smoking, mental pro-
cesses, arousal, mental recall, reaction time/s, decision time/s, pro-
cessing speed, performance, sensory, motor, psychomotor, attention, 
information processing, memory, cognition, electroencephalography, 
EEG, electroencephalogram/s, brain waves, alpha rhythm, beta 
rhythm, delta rhythm, gamma rhythm, theta rhythm, awake, asleep, 
slow-wave, sharp-wave, clinical trial/s, random allocation, 
humans, and not animal. Specific terms from these search 
threads were modified for certain databases in order to take 
advantage of unique search features and subheadings. The 
exact search threads for each database can be found in the 
Appendix.
Data collection
Data collection was completed in four phases.
Phase 1: Study selection: One reviewer (SP) scanned 
abstracts and evaluated them against the specific inclusion 
and exclusion criteria. Questions regarding the inclusion or 
exclusion of articles were resolved by discussion with the 
other authors.
Phase II: Full text analysis: After reviewing the abstracts, the 
remaining papers were extracted for full text review. The full 
text of each paper was reviewed by the authors (SP and PL) 
and coded for study characteristics as well as the authors’ 
reported overall judgment regarding the cognitive perfor-
mance effect of nicotine, categorized as: positive, negative, 
mixed effect, or no effect, based on overall effects across per-
formance domains and conclusions drawn by the authors. 
Author based their judgments on whether nicotine exposure 
reduced distraction, reduced response time, or facilitated 
memory consolidation; findings were coded as “positive” 
when authors concluded that nicotine had “beneficial” 
effects. At least one performance domain was identified per 
publication; measures used by the studies were heterogene-
ous, including free recall of word lists, card sorting, selective 
attention to auditory targets, letter matching on a computer 
screen, and visual attention to target images. Coding was 
done independently and both reviewers used a standardized 
coding instrument. A single coder (SP) extracted standard 
characteristics from each study, including study design and 
country, number of sessions attended by the participant, 
route of nicotine administration, gender, race/ethnicity, 
reported adverse events or other effects, reported funding 
source, and author affiliations.
Phase III: Risk of bias analysis: Following guidelines estab-
lished in the Cochrane Collaboration Handbook,16 two 
coders (SP & DA) coded for risk of bias. The following risk 
of bias was coded for each study: randomization, perfor-
mance, detection/desirability, author, and funding, including 
disclosure of funding source. Studies were coded as: high 
risk, low risk, or unclear risk for each type of bias. Allocation 
concealment, randomization, risk of author bias, detectabil-
ity of outcomes investigated, and blinding of participants 
were also assessed. The two coders independently coded the 
risk of bias, and coding tables were evaluated for discrepan-
cies, which were settled by discussion between the coders.
Phase IV: Funding source: Article funding disclosures, 
conflict of interest statements, and author affiliations were 
reviewed to determine industry funding. In addition to 
disclosures, the authors of the included papers were cross-
referenced using lists of supported researchers drawn from 
previously secret tobacco industry documents. These docu-
ments detailed studies funded by R.J. Reynolds Tobacco 
Company and Philip Morris USA,24–27 and were identified 
through previous research conducted by one of the authors 
(PL).28 Non-industry funding sources or affiliations were 
investigated for ties to the tobacco industry using the archive.
Analytical strategy
Statistical tests were conducted using Stata.29 Fisher’s exact 
tests calculated associations between funding source/affiliation 
and the type of reported cognitive effect (eg, positive versus 
negative/mixed/no effect). Reported outcomes from each study 
were categorized into four potential types: 1) positive, 2) nega-
tive, 3) mixed, or 4) no effect; for the statistical analysis, nega-
tive, mixed, and no effect were collapsed into one group. 
Industry affiliation was defined as the inclusion of at least one 
author who had ever worked for or received funds from either 
the tobacco or pharmaceutical industry. Funding sources or 
author affiliations for the tobacco industry could be disclosed, 
or undisclosed but identified through tobacco industry internal 
documents. Funding sources or author affiliations for the phar-
maceutical industry were only sourced from author disclosures. 
An odds ratio and 95% confidence interval was calculated 
between the industry affiliation and the reported positive cog-
nitive performance effect of nicotine.
Results
Study selection
We identified 3,771 abstracts from the literature search. From 
these, 54 full papers were extracted for full text review (see 
Figure 1). We excluded 22 studies for the following reasons:
•• Studies only explored the physiological effects of nicotine: Six 
studies were excluded due to only exploring the physio-
logical effects of nicotine with no cognitive or behavioral 
outcome measure.
•• Study population was not appropriate: Five studies were 
excluded due to inclusion of nicotine deprived partici-
pants. One study was excluded because smoking partici-
pants never abstained from smoking. One study was 
excluded due to participants >60 years of age.
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•• Study results were not usable: One study was excluded 
since for mixing outcomes of both healthy and patient 
participants. One study was excluded because it did not 
investigate a relevant performance domain. One study 
was excluded because all results were subjective.
•• Study design did not f it inclusion criteria: One study was 
excluded due to lack of randomization. Four studies were 
excluded because they were not double blinded.
•• Study intervention was not appropriate: One study was 
excluded because participants were only given placebos.
Figure 1. Prisma flow diagram.
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Study characteristics
After exclusions, 32 papers were included in the final system-
atic review,30–61 the majority of which used a cross-over design 
(n = 27; 84%). Table 1 summarizes the study characteristics. 
The summary table of studies is provided in the Appendix.
Risk of bias
We assessed risk of bias in six categories: (1) randomization; 
(2) performance; (3) detection/desirability; (4) funding; (5) 
author; and (6) publication. A summary of the analysis is pro-
vided in Table 1.
Table 1. Risk of bias assessments, all studies (n = 32).
STUDY RANDOMIZATION PERFORMANCE 
BIAS
DETECTION/ 
DESIRABLE BIAS
FUNDING AUTHOR
Beer et al.61 Low Risk Unclear Risk Unclear Risk Low Risk Low Risk
Behler et al.60 High Risk Low Risk High Risk Low Risk Low Risk
Bowling and donnelly59 Low Risk Unclear Risk High Risk Unclear Risk Low Risk
Breckel et al.58 Low Risk Low Risk Unclear Risk Low Risk Low Risk
ettinger et al. 2008 Low Risk Low Risk Unclear Risk Low Risk Low Risk
evans et al.56 Low Risk Low Risk Unclear Risk High Risk High Risk
Fisher et al.55 Low Risk Low Risk High Risk Unclear Risk High Risk
Fisher et al.54 Low Risk Low Risk High Risk Unclear Risk High Risk
Froeliger et al.53 Unclear Risk Unclear Risk High Risk Unclear Risk High Risk
giessing et al.52 Low Risk Low Risk Unclear Risk High Risk High Risk
greenstein et al.51 Low Risk Unclear Risk High Risk Unclear Risk Unclear Risk
holmes et al.50 Low Risk Low Risk High Risk High Risk Low Risk
impey et al.49 Low Risk Low Risk Unclear Risk Unclear Risk High Risk
knott et al.48 Low Risk Low Risk Unclear Risk Unclear Risk High Risk
knott et al.45 Low Risk Low Risk High Risk Low Risk High Risk
knott et al.46 Low Risk Low Risk High Risk Low Risk High Risk
knott et al.45(2) Unclear Risk Low Risk Unclear Risk High Risk High Risk
kobiella et al.44 2014 Low Risk Low Risk Unclear Risk High Risk Low Risk
niemegeers et al.43 Low Risk Low Risk High Risk High Risk High Risk
Petrovsky et al.41 Low Risk Low Risk Unclear Risk Low Risk Low Risk
Petrovsky et al.42 High Risk Low Risk Unclear Risk Low Risk High Risk
Pilarski et al.40 High Risk Unclear Risk Unclear Risk Unclear Risk Unclear Risk
Potter et al.39 Unclear Risk Low Risk Unclear Risk Unclear Risk Unclear Risk
Rigbi et al.38 Low Risk Low Risk Unclear Risk Low Risk High Risk
Rose et al.37 Low Risk Unclear Risk Unclear Risk Unclear Risk Low Risk
Rusted et al.36 Unclear Risk Low Risk Low Risk Unclear Risk Low Risk
Rusted et al.35 Low Risk Low Risk Unclear Risk High Risk Low Risk
Schmechtig et al.34 Low Risk Low Risk Low Risk High Risk Unclear Risk
Shah et al.33 Low Risk Low Risk High Risk Unclear Risk High Risk
Vangkilde et al.32 Low Risk Low Risk High Risk Low Risk Low Risk
wachter et al.31 Low Risk Low Risk Unclear Risk Low Risk High Risk
wignall et al.30 Low Risk Low Risk Unclear Risk Unclear Risk Unclear Risk
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(1) Randomization: The majority of the studies (n = 25 
of 32; 78%) were coded as low risk for bias arising from 
the randomization process. If the study had a cross over 
design and explicitly stated it was double-blinded and 
randomized then the study was coded as low risk. If the 
study did not explicitly state the study design was dou-
ble blinded and/or randomized and did not have a cross 
over design it was coded as unclear risk. Nine of the 
studies asked the participants if they could guess their 
allocation after each laboratory session (n = 4 of 32; 
13%). If the participants were able to correctly guess 
their allocations ⩾ 65% the study was coded as high 
risk due to signaling bias (n = 3 of 32; 9%).
(2) Performance: The majority of studies (n = 26 of 32; 
81%) were coded as low risk for performance bias based 
on blinding of participants and study personnel. If the 
study explicitly stated the design was double-blinded 
then the paper was coded as low risk. If the study did 
not explicitly stated the design was double-blinded then 
the paper was coded as unclear risk (n = 6 of 32; 19%).
(3) Detection/desirability: The majority of the studies (n 
= 18 of 32; 56%) were coded as unclear risk for detec-
tion/desirability bias based on whether participants 
were blinded to the study outcomes. If the participants 
knew what was being assessed then they might attempt 
to perform better in the area of assessment. Physiological 
assessments were not included. If the study had detect-
able subjective assessments and did not explicitly state 
that researchers had identified the area of assessment of 
the study to the participants, it was coded as unclear 
risk. Every included study assigned one or more cogni-
tive tasks to their participants. If the study offered 
training sessions for the participants to practice the 
cognitive task(s), supplied feedback to participants 
about their performance prior to the laboratory session, 
and required the participant to obtain a minimum score 
of correctness for the cognitive task(s) then the study 
was coded as high risk (n = 12 of 32; 38%). If the 
assessments were conducted by researchers unaware of 
the hypothesis, or the researchers assessed if partici-
pants improved their performance of the cognitive 
task(s) over time then the study was coded as low risk 
(n = 2 of 32; 6%).
(4) Funding: The studies showed different levels of risk for 
funding bias based on reported funding source and the 
conflict of interest statement. Funding source was 
coded as: government, academia, industry, or not stated. 
If a study did not state a funding source, was funded by 
a government grant/entity with no conflict of interest 
statement, or was funded by an academic source with 
no conflict of interest statement then it was coded as 
unclear risk (n = 13 of 32; 40%). If a study was funded 
by a government grant/entity or academic source and 
explicitly stated no conflicts then the study was coded 
as low risk (n = 10 of 32; 32%). If a study reported 
receiving nicotine supplies from a pharmaceutical com-
pany and/or funding from either the pharmaceutical or 
tobacco industry then the study was coded as high risk 
(n = 9 of 32; 28%).
(5) Author: The majority of studies were coded as high 
risk for author bias (n = 15 of 32; 47%) based on dis-
closed author affiliations with either pharmaceutical or 
tobacco affiliation and/or undisclosed author affilia-
tions with tobacco industry affiliation. Each study was 
also coded for the existence of a conflict of interest 
statement. If the study listed only academic affiliations 
for each author and the study had a conflict of interest 
statement stating no conflicts then the paper was coded 
as low risk (n = 12 of 32; 37%). If the study listed only 
academic affiliations for each author, but the study 
lacked a conflict of interest statement then the paper 
was coded as unclear risk (n= 5 of 32; 16%). If the study 
disclosed an industry affiliation, or an author of the 
study was affiliated with the tobacco industry and had 
not disclosed, the study was coded as high risk.
(6) Publication: The data collected from included articles 
were organized into a funnel diagram with range of 
reported outcomes on the x axis and the study popula-
tion size on the y axis to explore the likelihood of pub-
lication bias; this was asymmetrical and suggested the 
existence of publication bias (see Appendix).
Outcomes
The majority of studies used either a patch or gum as the route 
of nicotine administration (n = 11 and 13, respectively). Of the 
remaining studies, 3 used nasal spray and 1 each used oral spray, 
lozenge, injection, cigarette, and chewing tobacco. No study 
used multiple routes of administration. Most included studies 
were located in Canada (n = 8; 25%), Germany (n = 7; 22%), 
or in the US (n = 7; 22%). Of the remaining studies, 5 (16%) 
were conducted in the UK, 2 in Australia, and 1 each in Israel, 
Denmark, and Belgium.
Performance domains: The cognitive performance 
effects of nicotine were categorized into six performance 
domains: (1) attention; (2) long term memory; (3) motor 
sensory; (4) reasoning; (5) short term memory; (6) working 
memory. The majority of papers considered one performance 
domain; two papers explored two domains. The reported 
cognitive performance outcome of each paper was catego-
rized into 1 of 4 types: 1) positive; 2) negative; 3) mixed; or 
4) no effect. Of the 32 papers analyzed, the majority reported 
positive effects (n = 14; 43%) and explored attention (n = 
22; 69%). Results are provided in Table 2.
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Reported adverse events, mood, and change in vitals: 
Twenty-eight of the 32 studies assessed mood, change in 
vitals, and/or adverse events after administering nicotine. 
Sixteen studies investigated adverse events after the admin-
istration of nicotine. The most common adverse event 
reported was nausea (n = 7; 22%). The majority of the stud-
ies measured change in vital signs such as changes in heart 
rate and blood pressure (n = 18; 56%); the most common of 
these was increased heart rate (n = 8; 25%). Fifteen studies 
investigated mood after administration of nicotine. The 
reported findings on change of mood after nicotine adminis-
tration were mixed, but some trends were observed. For 
example six studies (19%) found no change in mood (n = 6; 
19%) and three studies (9%) reported similar findings related 
to wakefulness (ie, decrease in “tired”, “sleepiness”, and 
“fatigue”). Full descriptions of the reported adverse events, 
changes in mood, and changes in vitals for each study are 
provided in the Appendix.
Author affiliations: The 32 included studies involved 141 
authors. Most studies had 3 to 6 authors; the highest number 
of authors was 16. The names of all authors were cross refer-
enced to four lists of tobacco funded researchers.24–27 Of the 
141 authors, 11 authors were listed in tobacco industry 
documents as having received past industry funding. These 
11 authors were associated with 11 of the 32 included 
papers.31,33,38,45–49,53–55 All of these authors were associated with 
research funded by Philip Morris; two authors were also associ-
ated with research funded by R.J. Reynolds. The studies listed 
in the tobacco industry documents were conducted prior to the 
studies included in this review (1989-2008). None of these 
authors disclosed their past tobacco industry affiliation in the 
included studies.
Funding analysis: Seven studies explicitly stated that they 
had received funding from either the tobacco or pharmaceuti-
cal industry. Funding was defined as money or supplies received 
from either industry. No statistically significant association was 
found between reported funding source and outcome on the 
cognitive performance effects of nicotine.34,35,43–45,50,56 An 
additional two studies indicated other industry affiliations, 
defined as authors with current or past history in the form of 
either funding or a formal job title with either industry, for a 
total of 9 studies reporting industry affiliation of any kind. No 
statistically significant association was found between the 
funding source and the reported outcome on the cognitive per-
formance effects of nicotine.34,35,42-45,50,52,56
Our use of tobacco industry documents allowed us to iden-
tify additional undisclosed tobacco industry affiliations. If an 
author’s name was found on any of the unpublished tobacco 
funded research lists and they did not disclose the affiliation, 
then the study was coded as “undisclosed affiliated.” With these 
additional affiliations, a total of 19 studies were affiliated with 
either the tobacco or pharmaceutical industry. We found no sta-
tistically significant association between the funding source and 
the reported outcome on the cognitive performance effects of 
nicotine (OR = 0.804; 95% CI: 0.1 to 5.26).31,33–35,38,42–50,52–56
We also analyzed studies that were not affiliated with the 
tobacco industry (reported or unreported) and did not report a 
pharmaceutical industry affiliation. All studies coded as uncon-
flicted reported funding from a government grant or entity, 
contained a conflict of interest statement which reported no 
conflicts, and did not include authors with unreported affilia-
tions with the tobacco industry identified through internal 
industry documents. Undisclosed pharmaceutical funding 
could not be assessed. Five studies were coded as unconflicted; 
four of these studies investigated the effects of nicotine in the 
performance domain attention. Of these, two reported positive 
effects on attention and two reported mixed effects on atten-
tion. This outcome was similar to the distribution of reported 
outcomes in the performance domain of attention across all 32 
studies included in this systematic review. Specifically, 22 of the 
32 studies explored the performance domain of attention and 
the distribution of reported outcomes were: positive (n = 9 of 
22; 41%); negative (n = 0 of 22; 0%); mixed (n = 9 of 22; 41%); 
and no effect (n = 4 of 22; 18%). A summary of the uncon-
flicted studies is provided in Table 3.
Discussion
The objectives of this systematic review, which included 32 
randomized controlled trials, were to assess the cognitive per-
formance effects of nicotine among health adults in recent 
Table 2. Performance domains and reported outcomes, all studies (n = 32).
REPORTED OUTCOME ATTENTION LTM MS REASONING STM WM
Positive 9 2 1 – 1 1
negative 0 – – – – 1
mixed 9 – – – – 1
no effect 4 2 1 1 – 1
Total 22 4 2 1 1 4
Abbreviations: LTM, long term memory; MS, motor sensory; STM, short term memory; WM, working memory.
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studies by updating a systematic review completed in 2010,6 
and to identify whether outcomes were associated with indus-
try affiliations. Past studies suggest that nicotine administra-
tion might increase attention, based on a range of measures.6,16 
Our review did not identify a similar effect, despite the high 
likelihood of publication bias. Although the majority of studies 
evaluated in this review focused on attention (n = 22, 69%), 
there was no consistent outcome for the cognitive performance 
effects of nicotine on attention. Our results could reflect publi-
cation bias, changes in study design, reliance on different cog-
nitive tests, or use of updated technology.
We hypothesized that authors with current or past tobacco 
and/or pharmaceutical industry funding would be more likely 
to report positive effects on cognitive performance. No statis-
tically significant association was observed. Less stringent 
inclusion and exclusion criteria than those adopted from the 
2010 meta-analysis would have identified more papers of 
potentially lower quality, which has been associated with 
industry funding in the past62; however including these papers 
would likely further increase publication bias and the incon-
sistency of research results.
Our findings also revealed that authors generally did not 
disclose their industry affiliations. Only one study in our sys-
tematic review reported tobacco industry sponsorship, although 
review of tobacco industry documents revealed that 10 addi-
tional studies had past tobacco industry affiliations. There is no 
consistent standard among journals regarding the time period 
for which authors must disclose support from organizations 
with a conflict of interest; required reporting may range from 
only support of the published manuscript to support over mul-
tiple years.18,63,64 When a longer time period was considered, 
authors had substantially more industry affiliations; consider-
ing that our sources only allowed us to identify past tobacco 
industry funding, and not past pharmaceutical industry fund-
ing, our results likely underestimate pharmaceutical industry 
affiliations.
This systematic review has limitations. The inclusion and 
exclusion criteria of the most recent meta-analysis on this topic 
were adopted to ensure consistency with prior work, however 
this choice meant that we included a small set of studies in the 
analysis. For example, novel nicotine delivery systems, such as 
electronic cigarettes, were not included in this systematic 
review because no studies using this mode of nicotine delivery 
met the inclusion criteria. The potential bias due to past indus-
try affiliation may be understated given that we could not 
identify unreported pharmaceutical industry affiliations. The 
studies included in this systematic review are more rigorous 
randomized controlled trials, but less generalizable to the over-
all public, due to laboratory setting and conducted in a limited 
number of countries. Using less restrictive inclusion criteria 
could have identified additional studies and increased the like-
lihood of identifying potentially significant associations. In 
addition to the high risks of funding bias, our risk of bias 
assessment also found that all but two studies showed high risk 
of detection/desirability bias, and a risk of publication bias, 
raising the possibility that unpublished results may have shown 
insignificant effects, or significant effects that the authors or 
funders preferred not to publish.
This systematic review, like earlier research, found incon-
sistent results regarding the cognitive performance effects of 
nicotine, as well as indeterminate effects of past industry 
funding. Our findings identified underreported industry 
affiliations and the existence of publication bias, suggesting 
that research in this area may become more definitive with 
improved reporting of author affiliations. More than half of 
the papers with past tobacco industry affiliations did not dis-
close these relationships. Further research on the effects of 
nicotine with respect to cognitive performance, and its safety, 
is needed, particularly given that research on cognitive perfor-
mance effects of nicotine, although inconclusive, are used 
selectively to advocate for consumption of tobacco products. 
Research on nicotine will continue to be difficult to assess 
without complete and transparent reporting of past and cur-
rent industry affiliations.
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